University of Notre Dame DU Lac purchased a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 157,781 shares of the biopharmaceutical company’s stock, valued at approximately $2,824,000. University of Notre Dame DU Lac owned about 0.35% of Vanda Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of VNDA. Schwab Charles Investment Management Inc. increased its position in Vanda Pharmaceuticals by 2.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock valued at $8,459,000 after buying an additional 11,647 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Vanda Pharmaceuticals by 112.2% in the 3rd quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after purchasing an additional 80,209 shares in the last quarter. Cadence Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth $1,121,000. Rothschild Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth $23,491,000. Finally, Cortina Asset Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 423.6% in the 3rd quarter. Cortina Asset Management LLC now owns 212,503 shares of the biopharmaceutical company’s stock worth $3,804,000 after purchasing an additional 171,918 shares in the last quarter. Institutional investors and hedge funds own 88.45% of the company’s stock.

Several brokerages recently commented on VNDA. Zacks Investment Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies lifted their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. Jefferies Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $21.50.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at $14.05 on Wednesday. Vanda Pharmaceuticals Inc. has a 52-week low of $11.90 and a 52-week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The business had revenue of $41.30 million for the quarter, compared to the consensus estimate of $43.90 million. During the same period in the previous year, the business earned ($0.01) earnings per share. The business’s revenue was up 7.3% on a year-over-year basis. analysts forecast that Vanda Pharmaceuticals Inc. will post -0.42 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/university-of-notre-dame-du-lac-invests-2-82-million-in-vanda-pharmaceuticals-inc-vnda/1747130.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.